Access the full text.
Sign up today, get DeepDyve free for 14 days.
C Massard, J Zonierek, A Laplanche (2006)
Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinas inhibitorAnn Oncol, 17
N. Kuwashima, Fumihiko Nishimura, J. Eguchi, Hidemitsu Sato, M. Hatano, T. Tsugawa, T. Sakaida, Jill Dusak, W. Fellows-Mayle, G. Papworth, Simon Watkins, A. Gambotto, I. Pollack, W. Storkus, H. Okada (2005)
Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1The Journal of Immunology, 175
N. Choong, S. Dietrich, T. Seiwert, M. Tretiakova, V. Nallasura, G. Davies, S. Lipkowitz, A. Husain, R. Salgia, P. Ma (2006)
Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutationNature Clinical Practice Oncology, 3
J. Vredenburgh, A. Desjardins, J. Herndon, J. Marcello, D. Reardon, J. Quinn, J. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, Melissa Wagner, L. Bailey, D. Bigner, A. Friedman, H. Friedman (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 30
C. Gridelli, P. Maione, D. Galetta, G. Colantuoni, F. Gaizo, C. Ferrara, C. Guerriero, D. Nicolella, A. Rossi (2007)
Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2
A. Madhankumar, Becky Slagle-Webb, A. Mintz, J. Sheehan, J. Connor (2006)
Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiformeMolecular Cancer Therapeutics, 5
C. Massard, E. Deutsch, J. Soria (2006)
Tumour stem cell-targeted treatment: elimination or differentiation.Annals of oncology : official journal of the European Society for Medical Oncology, 17 11
H. Yokouchi, K. Yamazaki, I. Kinoshita, J. Konishi, H. Asahina, N. Sukoh, M. Harada, K. Akie, S. Ogura, T. Ishida, M. Munakata, H. Dosaka-akita, H. Isobe, M. Nishimura (2007)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancerBMC Cancer, 7
W. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O’Shaughnessy (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
NU Lin, V Dieras, D Paul, D Lossignol, C Christodoulou, D Lasessig, H Roche, D Zembryki, CR Oliva, EP Winer (2007)
EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (h) based systemic therapy and cranial radiotherapyProc Am Soc Clin Oncol, 25
J. Medioni, O. Cojocarasu, Belcaceres Jl, P. Halimi, S. Oudard (2007)
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 18 7
D. Pouessel, S. Culine (2008)
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.European urology, 53 2
N. Lin, V. Diéras, D. Paul, D. Lossignol, C. Christodoulou, D. Laessig, H. Roché, D. Zembryki, C. Oliva, E. Winer (2007)
EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)Journal of Clinical Oncology, 25
R. Saito, J. Bringas, Amith Panner, Matyas Tamas, R. Pieper, M. Berger, K. Bankiewicz (2004)
Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft ModelCancer Research, 64
A. Mancuso, M. Migliorino, S. Santis, A. Saponiero, F. Marinis (2006)
Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 17 1
R. Saito, M. Krauze, C. Noble, D. Drummond, D. Kirpotin, M. Berger, John Park, K. Bankiewicz (2006)
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.Neuro-oncology, 8 3
E. Mastrobattista, M. Aa, W. Hennink, D. Crommelin (2006)
Artificial viruses: a nanotechnological approach to gene deliveryNature Reviews Drug Discovery, 5
S. Yano, H. Shinohara, R. Herbst, Hiroki Kuniyasu, C. Bucana, L. Ellis, D. Davis, D. McConkey, I. Fidler (2000)
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.Cancer research, 60 17
S. Benedetti, B. Pirola, B. Pollo, L. Magrassi, M. Bruzzone, D. Rigamonti, R. Galli, S. Selleri, F. Meco, Claudio Fraja, A. Vescovi, E. Cattaneo, G. Finocchiaro (2000)
Gene therapy of experimental brain tumors using neural progenitor cellsNature Medicine, 6
R. Patchell, P. Tibbs, J. Walsh, R. Dempsey, Y. Maruyama, R. Kryscio, W. Markesbery, J. Macdonald, Byron Young (1990)
A randomized trial of surgery in the treatment of single metastases to the brain.The New England journal of medicine, 322 8
M. Ewend, S. Brem, M. Gilbert, R. Goodkin, P. Penar, M. Varia, S. Cush, L. Carey (2007)
Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local ControlClinical Cancer Research, 13
Meng‐Lay Lin, Jae-Hyun Park, Toshihiko Nishidate, Yusuke Nakamura, T. Katagiri (2007)
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 familyBreast Cancer Research, 9
The rapid development of targeted therapies capable of entering the brain and the emerging technology of nano shells armed with cytotoxins reflects promising progress in the treatment of brain metastasis. The management of brain metastases is complicated by a number of major problems. The histological, molecular, biologic and immunologic nature of the various tumour types metastasizing to the brain differs significantly. As a consequence, the sensitivity towards various cytotoxic drugs or other treatment options varies substantially. Only few drugs are usually considered capable of penetrating the blood/brain and the brain/liquor barriers. Thus, the availability of a drug with adequate molecular size and pharmacokinetics within the compartments of the central nervous system determine the usage of cytotoxic drugs rather than the sensitivity of a specific tumour type to a specific drug. Recently, however, progress has been made in the development of more efficient types of therapy against brain metastases.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.